SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 339 shares, a decline of 73.4% from the April 15th total of 1,276 shares. Based on an average trading volume of 7,336 shares, the short-interest ratio is currently 0.0 days.
SAB Biotherapeutics Trading Down 28.1%
Shares of SAB Biotherapeutics stock traded down $0.01 during trading hours on Thursday, reaching $0.02. 30,794 shares of the company’s stock were exchanged, compared to its average volume of 22,398. SAB Biotherapeutics has a 52-week low of $0.02 and a 52-week high of $0.18. The company has a fifty day moving average of $0.03 and a 200-day moving average of $0.03.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Read More
- Five stocks we like better than SAB Biotherapeutics
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
